Urology Times staff

"The first takeaway I would say is that there is not only a lot of passion for each of these different areas in our society, but also there's a lot of expertise and experience within our urologic community from which we can all draw upon," says Manoj Monga, MD, FACS.

“These are codes that had not been updated in decades—since they were originally written,” says Jonathan Rubenstein, MD.

“I think really identifying who's going to benefit from what combination for how long is going to be important,” says Stephanie Berg, DO.

Several treatments are being explored across these trials, including pembrolizumab, nivolumab, enfortumab vedotin, durvalumab, avelumab, and cabozantinib.

“Now, we only have 1 code set that we have to worry about instead of 2 code sets,” says Jonathan Rubenstein, MD.

“We don’t want to subject patients to a therapeutic strategy that they are unlikely to benefit from,” says Atish D. Choudhury, MD, PhD.

“Practices need to be aware that they need to be able to budget for those who perform in-office services that have very little clinical labor, but may have a high practice expense overall,” Jonathan Rubenstein, MD, says.

“Every year, we see our reimbursements go down. Every year, there seem to be some sort of patch,” says Jonathan Rubenstein, MD.

“There are a slew of ongoing trials looking at 177Lu-PSMA-617 in earlier stages of disease,” says Praful Ravi, MB, BChir, MRCP.

“We have to remember that this is not a cure for prostate cancer…right now, it is another tool in the toolbox,” says Praful Ravi, MB, BChir, MRCP.

“We found many factors in urology that were associated with the inability to follow through with a video visit,” says Kevin Shee, MD, PhD.

In this interview, Arvin K. George, MD, gives an overview of the current state of focal therapy and also discusses 2 clinical trials evaluating new technologies in the space.

Slovin says what’s interesting about the CAR-T platform she’s been exploring is that “we see pretty exquisite sensitivity to the cancer cells.”

"[Low-grade prostate cancer] is a really interesting field right now," says Kevin Shee, MD, PhD.

“The takeaway from that talk was that it's critically important to review drug plan options, particularly if the patient's on a high-cost drug,” says Kelly L. Stratton, MD, FACS.

“The idea of generally screening everyone right now is not only costly, but it's not recognizing the fact that this comes with a lot of limitations,” says Mark A. Moyad, MD, MPH.

Ashley E. Ross, MD, PhD, provides an overview of his institution’s new protocol for this subset of patients.

“[The 2022 Huggins Medal Lecture from Harry Herr, MD] was a fascinating talk, and something that I think anyone could learn from,” says Kelly L. Stratton, MD, FACS.

“It was vitamin E and selenium in 2011-2012. There was a lot of hype about it. People were very excited. They lost their excitement in urology about it, but then along came vitamin D,” says Mark A. Moyad, MD, MPH.

“I think [it was a] great opportunity to catch up on what is going on with PSMA-PET and theranostics and then also understand that that landscape will change over the near future,” says Kelly L. Stratton, MD, FACS.

“It really was a multidisciplinary effort to pull the data together [and] provide the clinical implications [of] the genetic markers,” says Veda N. Giri, MD.

“It's very interesting to see how this continues to progress as a field,” says Kelly L. Stratton, MD FACS.

“Clinicians should do whatever they're able to try to limit or reduce the need for an intraoperative transfusion,” says Timothy D. Lyon, MD, FACS.

“The bulk of what we’re all grappling with are these new data for combining PARP inhibitors with androgen receptor–targeted agents in molecularly unselected populations,” says Tanya Dorff, MD.

“Major bladder reconstructive surgeries have the most room for improvement, particularly surgeries involving a bowel anastomosis,” says Sarah Hecht, MD.

“As people think about how we can do stone surgery more effectively, less morbidly for our patients, and less invasively, I think we're going to see robots enter our picture,” says Thomas Chi, MD.

“We need to be focusing our efforts on early exposure to the field for women and underrepresented groups,” says Bridget Lang Findlay, MD.

“It's important to put out information that's both accurate and helps to supplement in-office decision making in an outpatient setting,” says Daniel Bockelman.

Laura Bukavina, MD, MPH, discusses a highlight from the 2022 Society of Urologic Oncology Annual Meeting.

“We've got a lot of movement in terms of understanding how stones form, some pharmaceutical interventions that we can use to prevent stones, and then how we can get even less invasive to try to get stones in the least morbid way for our patients,” says Thomas Chi, MD.